图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017017912
pages 63-96

Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine’s Drug Conjugates on Cancer Therapy

Sathish Dyawanapelly
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, 229 010, India
Animesh Kumar
Pharmaceutics Division, CSIR-Central Drug Research Institute, Lucknow, 226 013, India
Manish K. Chourasia
Pharmaceutics Division, CSIR-Central Drug Research Institute, Lucknow, 226 013, India

ABSTRACT

Currently, drug delivery systems have a high impact in cancer therapy and are receiving more attention than conventional cancer treatment modalities. Compared with current cancer therapies, gemcitabine (2', 2'-difluoro-2'-deoxycytidine) has been proven to be an effective chemotherapeutic agent against pancreatic, colon, bladder, breast, ovarian, non-small-cell lung, and head and neck cancers in combination with other anticancer agents. To improve the safety and efficacy of cytotoxic drugs, several drug delivery systems have been explored. This review outlines the recent work directed toward gemcitabine delivery systems for cancer therapy, including aerosols, polymeric nanoparticles, liposomes, microparticles, carbon nanotubes, and multifunctional theranostic nanomedicines. It also provides insight into the design and development of gemcitabine conjugation for safe and effective cancer therapy. Despite the clinical promises of gemcitabine, many therapeutic challenges remain. Specifically, its therapeutic use in cancer chemotherapy is impeded by a short biological half-life, caused by its rapid metabolism, and resistance due to increased expression of ribonucleotide reductase. In our opinion, many research investigations have contributed to improve the selectivity and efficacy of gemcitabine. This combined approach of drug delivery systems and gemcitabine conjugates has shown promising efficacy in preclinical models and significant potential for future clinical cancer-therapeutic applications. Also, these strategies overcome most of the aforementioned limits of gemcitabine.


Articles with similar content:

Solid Lipid Nanoparticles: Vital Characteristics and Prospective Applications in Cancer Treatment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 6
Lucia R. Tefas, Diana Tudor, Elena Diana Olteanu, Marcela Achim, Claudia Burz, Iuliana Nenu, Gabriela Adriana Filip, Ioana Baldea, Leontin F. Lazăr, Simona Clichici, Radu Iuga
Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 5
Shivani Saraf, Ankit Jain, Pooja Hurkat, Sanjay Kumar Jain
Optimizing Drug Delivery for Enhancing Therapeutic Efficacy of Recombinant Human Endostatin in Cancer Treatment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 5
Huanchen Sha, Fuguo Xu, Qingyong Ma
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey
Therapeutic Opportunities in Colon-Specific Drug-Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 2
Avani Amin, Mayur M. Patel, Tejal Shah